Evidence map›Paper›PMID 40464813›Full record

ArticleCancer immunology, immunotherapy : CII2025

Single-cell RNA sequencing analysis reveals a lack of CXCL13

Xia Li, Yanmei Cheng, Mei Ji, Junqi Liu, Zhao Zhao, Qitai Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xia LiDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Yanmei ChengDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Mei JiDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Junqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Zhao ZhaoDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Qitai ZhaoBiotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China. zhaoqitai845626@126.com.

Funding

Henan Provincial Medical Science and Technology Research Joint Construction Project LHGJ20240200Henan Provincial Natural Science Foundation 242300420396the Postdoctoral Fellowship Program (Grade C)of China Postdoctoral Science Foundation GZC20232435
6 · The paper itself

Abstract

Concurrent chemoradiotherapy (CCRT) is the standard treatment for advanced cervical cancer, but tumor recurrence within 3-5 years remains a significant challenge. In this study, using 10 × single-cell sequencing, we constructed a cellular atlas of the tumor microenvironment from six CSCC patients, including three with recurrence and three without, prior to CCRT. We analyzed cellular subsets, focusing on T cells, myeloid cells and cancer associated fibroblasts (CAFs), and their interactions within the tumor. Key findings revealed that CXCL13

Indexed as

Carcinoma, Squamous CellChemokine CXCL13Neoplasm Recurrence, LocalT-Lymphocyte SubsetsUterine Cervical NeoplasmsBiomarkers, TumorChemoradiotherapyFemaleHumansMiddle AgedSequence Analysis, RNASingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorChemokine CXCL13CXCL13 protein, humanCell communicationCervical squamous cell carcinomaConcurrent chemoradiotherapyCXCL13+ T cellsRandom forest modelRecurrence

Identifiers

PMID40464813
PMCPMC12137842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.